Advertisement

The Art and Science of Using Diuretics in the Treatment of Heart Failure in Diverse Clinical Settings

  • Md. Shahidul IslamEmail author
Chapter
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 1067)

Abstract

It is important to understand the rationale for appropriate use of different diuretics, alone or in combination, in different heart failure patients, under diverse clinical settings. Clinicians and nurses engaged in heart failure care, must be familiar with different diuretics, their appropriate doses, methods of administration, monitoring of the responses, and the side-effects. Inappropriate use of diuretics, both under-treatment and overtreatment, and poor follow-up can lead to failures, and adverse outcomes. Adequate treatment of congestion, with rather aggressive use of diuretics, is necessary, even if that may worsen renal function temporarily in some patients. Diuretic treatment should later be titrated down, by early recognition of the euvolemic sate, which can be assessed by clinical examination, measurement of the natriuretic peptides, and when possible, echocardiographic estimation of the left ventricular filling pressure. You need to treat patients, who are truly resistant to the loop diuretics, by administering the diuretics as intravenous bolus injection followed by continuous infusion, and/or by sequential nephron blockade by adding the thiazide diuretics. You need to use the diuretics based on a sound understanding of the pathophysiology of the disease process, the pharmacokinetics and pharmacodynamics of the diuretics, even when strong evidences for your choices might be lacking. Some patients may benefit from injection of loop diuretics together with hypertonic saline, and others from injection of loop diuretics with albumin. Patient education, and regular follow up of the treatment of heart failure patients, in out-patient settings are important for reducing the rates of complications, and for reducing the needs for urgent hospitalizations.

Keywords

Albumin in heart failure Bumetanide in heart failure Diuretic algorithm in heart failure Diuretic dose in heart failure Diuretic infusion in heart failure Diuretic resistance in heart failure Diuretics in heart failure Hypertonic saline in heart failure Loop diuretics in heart failure Sequential nephron blockade Thiazides in heart failure Torsemide in heart failure 

Notes

Acknowledgement

Financial support was obtained from the Karolinska Institute, Stockholm, Sweden, and the Uppsala County Council, Uppsala University Hospital, Department of Emergency Care and Internal Medicine, Uppsala University, Sweden.

Conflicts of Interests

The author declares that he has no conflicts of interest concerning the publication of this paper.

References

  1. Barber J, McKeever TM, McDowell SE, Clayton JA, Ferner RE, Gordon RD et al (2015) A systematic review and meta-analysis of thiazide-induced hyponatraemia: time to reconsider electrolyte monitoring regimens after thiazide initiation? Br J Clin Pharmacol 79(4):566–577CrossRefPubMedGoogle Scholar
  2. Brater DC (1998) Diuretic therapy. N Engl J Med 339(6):387–395CrossRefPubMedGoogle Scholar
  3. Brater DC (2011) Update in diuretic therapy: clinical pharmacology. Semin Nephrol 31(6):483–494CrossRefPubMedGoogle Scholar
  4. Buckley LF, Carter DM, Matta L, Cheng JW, Stevens C, Belenkiy RM et al (2016) Intravenous diuretic therapy for the Management of Heart Failure and Volume Overload in a multidisciplinary outpatient unit. JACC Heart Fail. 4(1):1–8CrossRefPubMedGoogle Scholar
  5. Butler J, Anstrom KJ, Felker GM, Givertz MM, Kalogeropoulos AP, Konstam MA et al (2017) Efficacy and safety of spironolactone in acute heart failure: the ATHENA-HF randomized clinical trial. JAMA Cardiol 2(9):950–958CrossRefPubMedPubMedCentralGoogle Scholar
  6. Catlin JR, Adams CB, Louie DJ, Wilson MD, Louie EN (2018) Aggressive versus conservative initial diuretic dosing in the emergency department for acute decompensated heart failure. Ann Pharmacother 52(1):26–31CrossRefPubMedGoogle Scholar
  7. Cooper HA, Dries DL, Davis CE, Shen YL, Domanski MJ (1999) Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction. Circulation 100(12):1311–1315CrossRefPubMedGoogle Scholar
  8. Cosin J, Diez J, investigators T (2002) Torasemide in chronic heart failure: results of the TORIC study. Eur J Heart Fail 4(4):507–513CrossRefPubMedGoogle Scholar
  9. Costanzo MR, Guglin ME, Saltzberg MT, Jessup ML, Bart BA, Teerlink JR et al (2007) Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol 49(6):675–683CrossRefPubMedGoogle Scholar
  10. Dini FL, Carluccio E, Montecucco F, Rosa GM, Fontanive P (2017) Combining echo and natriuretic peptides to guide heart failure care in the outpatient setting: a position paper. Eur J Clin Investig 47(12):e12846CrossRefGoogle Scholar
  11. Duffy M, Jain S, Harrell N, Kothari N, Reddi AS (2015) Albumin and furosemide combination for Management of Edema in Nephrotic syndrome: a review of clinical studies. Cell 4(4):622–630CrossRefGoogle Scholar
  12. Dunlap ME, Hauptman PJ, Amin AN, Chase SL, Chiodo JA 3rd, Chiong JR et al (2017) Current Management of Hyponatremia in acute heart failure: a report from the hyponatremia registry for patients with Euvolemic and Hypervolemic hyponatremia (HN registry). J Am Heart Assoc 6(8):e005261CrossRefPubMedPubMedCentralGoogle Scholar
  13. Fallick C, Sobotka PA, Dunlap ME (2011) Sympathetically mediated changes in capacitance: redistribution of the venous reservoir as a cause of decompensation. Circ Heart Fail 4(5):669–675CrossRefPubMedGoogle Scholar
  14. Faris RF, Flather M, Purcell H, Poole-Wilson PA, Coats AJ (2012) Diuretics for heart failure. Cochrane Database Syst Rev 2:CD003838Google Scholar
  15. Felker GM, Lee KL, Bull DA, Redfield MM, Stevenson LW, Goldsmith SR et al (2011) Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med 364(9):797–805CrossRefPubMedPubMedCentralGoogle Scholar
  16. Felker GM, Mentz RJ, Cole RT, Adams KF, Egnaczyk GF, Fiuzat M et al (2017) Efficacy and safety of Tolvaptan in patients hospitalized with acute heart failure. J Am Coll Cardiol 69(11):1399–1406CrossRefPubMedGoogle Scholar
  17. From AM, Lam CS, Pitta SR, Kumar PV, Balbissi KA, Booker JD et al (2011) Bedside assessment of cardiac hemodynamics: the impact of noninvasive testing and examiner experience. Am J Med 124(11):1051–1057CrossRefPubMedGoogle Scholar
  18. Gandhi S, Mosleh W, Myers RB (2014) Hypertonic saline with furosemide for the treatment of acute congestive heart failure: a systematic review and meta-analysis. Int J Cardiol 173(2):139–145CrossRefPubMedGoogle Scholar
  19. Gilotra NA, Princewill O, Marino B, Okwuosa IS, Chasler J, Almansa J et al (2018) Efficacy of intravenous furosemide versus a novel, pH-neutral furosemide formulation administered subcutaneously in outpatients with worsening heart failure. JACC Heart Fail 6(1):65–70CrossRefPubMedGoogle Scholar
  20. Greene SJ, Gheorghiade M, Vaduganathan M, Ambrosy AP, Mentz RJ, Subacius H et al (2013) Haemoconcentration, renal function, and post-discharge outcomes among patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial. Eur J Heart Fail 15(12):1401–1411CrossRefPubMedPubMedCentralGoogle Scholar
  21. Grodin JL, Stevens SR, de Las Fuentes L, Kiernan M, Birati EY, Gupta D et al (2016a) Intensification of medication therapy for cardiorenal syndrome in acute decompensated heart failure. J Card Fail 22(1):26–32CrossRefPubMedGoogle Scholar
  22. Grodin JL, Lala A, Stevens SR, DeVore AD, Cooper LB, AbouEzzeddine OF et al (2016b) Clinical implications of serum albumin levels in acute heart failure: insights from DOSE-AHF and ROSE-AHF. J Card Fail 22(11):884–890CrossRefPubMedPubMedCentralGoogle Scholar
  23. Imiela T, Budaj A (2017) Acetazolamide as add-on diuretic therapy in exacerbations of chronic heart failure: a pilot study. Clin Drug Investig 37(12):1175–1181CrossRefPubMedPubMedCentralGoogle Scholar
  24. Jentzer JC, DeWald TA, Hernandez AF (2010) Combination of loop diuretics with thiazide-type diuretics in heart failure. J Am Coll Cardiol 56(19):1527–1534CrossRefPubMedGoogle Scholar
  25. Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A et al (2004) Rates of hyperkalemia after publication of the randomized Aldactone evaluation study. N Engl J Med 351(6):543–551CrossRefPubMedGoogle Scholar
  26. Klein L, O'Connor CM, Leimberger JD, Gattis-Stough W, Pina IL, Felker GM et al (2005) Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the outcomes of a prospective trial of intravenous Milrinone for exacerbations of chronic heart failure (OPTIME-CHF) study. Circulation 111(19):2454–2460CrossRefPubMedGoogle Scholar
  27. Konstam MA, Kiernan M, Chandler A, Dhingra R, Mody FV, Eisen H et al (2017) Short-term effects of Tolvaptan in patients with acute heart failure and volume overload. J Am Coll Cardiol 69(11):1409–1419CrossRefPubMedGoogle Scholar
  28. Licata G, Di Pasquale P, Parrinello G, Cardinale A, Scandurra A, Follone G et al (2003) Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as bolus in refractory congestive heart failure: long-term effects. Am Heart J 145(3):459–466CrossRefPubMedGoogle Scholar
  29. Martens P, Verbrugge FH, Boonen L, Nijst P, Dupont M, Mullens W (2018) Value of routine investigations to predict loop diuretic down-titration success in stable heart failure. Int J Cardiol 250:171–175CrossRefPubMedGoogle Scholar
  30. Murray MD, Haag KM, Black PK, Hall SD, Brater DC (1997) Variable furosemide absorption and poor predictability of response in elderly patients. Pharmacotherapy 17(1):98–106PubMedGoogle Scholar
  31. Murray MD, Deer MM, Ferguson JA, Dexter PR, Bennett SJ, Perkins SM et al (2001) Open-label randomized trial of torsemide compared with furosemide therapy for patients with heart failure. Am J Med 111(7):513–520CrossRefPubMedGoogle Scholar
  32. Ng KT, Yap JLL (2018) Continuous infusion vs. intermittent bolus injection of furosemide in acute decompensated heart failure: systematic review and meta-analysis of randomised controlled trials. Anaesthesia 73(2):238–247CrossRefPubMedGoogle Scholar
  33. Paterna S, Fasullo S, Parrinello G, Cannizzaro S, Basile I, Vitrano G et al (2011) Short-term effects of hypertonic saline solution in acute heart failure and long-term effects of a moderate sodium restriction in patients with compensated heart failure with New York heart association class III (class C) (SMAC-HF study). Am J Med Sci 342(1):27–37CrossRefPubMedGoogle Scholar
  34. Paterna S, Di Gaudio F, La Rocca V, Balistreri F, Greco M, Torres D et al (2015) Hypertonic saline in conjunction with high-dose furosemide improves dose-response curves in worsening refractory congestive heart failure. Adv Ther 32(10):971–982CrossRefPubMedPubMedCentralGoogle Scholar
  35. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS et al (2016) ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Rev Esp Cardiol (Engl Ed) 69(12):1167CrossRefGoogle Scholar
  36. Regolisti G, Fiaccadori E (2013) Ultrafiltration in acute decompensated heart failure: friend or foe for the kidney? J Nephrol 26(3):421–426CrossRefPubMedGoogle Scholar
  37. Roush GC, Kaur R, Ernst ME (2014) Diuretics: a review and update. J Cardiovasc Pharmacol Ther 19(1):5–13CrossRefPubMedGoogle Scholar
  38. Shah KB, Rao K, Sawyer R, Gottlieb SS (2005) The adequacy of laboratory monitoring in patients treated with spironolactone for congestive heart failure. J Am Coll Cardiol 46(5):845–849CrossRefPubMedGoogle Scholar
  39. Soleimani M (2015) The multiple roles of pendrin in the kidney. Nephrol Dial Transplant 30(8):1257–1266CrossRefPubMedGoogle Scholar
  40. Ter Maaten JM, Rao VS, Hanberg JS, Perry Wilson F, Bellumkonda L, Assefa M et al (2017) Renal tubular resistance is the primary driver for loop diuretic resistance in acute heart failure. Eur J Heart Fail 19(8):1014–1022CrossRefPubMedGoogle Scholar
  41. Testani JM, Chen J, McCauley BD, Kimmel SE, Shannon RP (2010) Potential effects of aggressive decongestion during the treatment of decompensated heart failure on renal function and survival. Circulation 122(3):265–272CrossRefPubMedPubMedCentralGoogle Scholar
  42. van der Meer P, Postmus D, Ponikowski P, Cleland JG, O'Connor CM, Cotter G et al (2013) The predictive value of short-term changes in hemoglobin concentration in patients presenting with acute decompensated heart failure. J Am Coll Cardiol 61(19):1973–1981CrossRefPubMedGoogle Scholar
  43. Verbrugge FH, Steels P, Grieten L, Nijst P, Tang WH, Mullens W (2015) Hyponatremia in acute decompensated heart failure: depletion versus dilution. J Am Coll Cardiol 65(5):480–492CrossRefPubMedGoogle Scholar
  44. Wan SH, Stevens SR, Borlaug BA, Anstrom KJ, Deswal A, Felker GM et al (2016) Differential response to low-dose dopamine or low-dose Nesiritide in acute heart failure with reduced or preserved ejection fraction: results from the ROSE AHF trial (renal optimization strategies evaluation in acute heart failure). Circ Heart Fail 9(8):e002593CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG 2018

Authors and Affiliations

  1. 1.Department of Clinical Science and Education, SödersjukhusetKarolinska Institutet, Research CenterStockholmSweden
  2. 2.Department of Emergency Care and Internal Medicine, Uppsala University HospitalUppsala UniversityUppsalaSweden

Personalised recommendations